FDA nod for Zolgensma in SMA; marks approval of most-expensive drug ever

25 May 2019
novartis_basel_stock_large

The US Food and Drug Administration on Friday approved Zolgensma (onasemnogene abeparvovec-xioi), the first gene therapy approved to treat children less than two years of age with spinal muscular atrophy (SMA), the most severe form of SMA and a leading genetic cause of infant mortality.

The label for Zolgensma, a one-time treatment, has a less restrictive age limitation than analysts had anticipated. Importantly it will also allow Zolgensma to capture all Type 1 and Type 2 SMA patients without the need of newborn screening – Type 1 patients develop symptoms by 6 months of age, and Type 2 patients typically develop symptoms between the ages of 7 to 18 months, noted SVB Leerink Research analyst Mani Foroohar.

Following the FDA announcement, the gene therapy’s developer AveXis, a subsidiary of Swiss pharma giant Novartis (NOVN: VX) company, announced innovative access programs for Zolgensma for the treatment of pediatric patients less than two years of age with SMA with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology